Mizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 37cMay 14, 2024 4:25 PM Form 10-Q Arcutis Biotherapeutics, For: Mar 31May 14, 2024 4:11 PM Form 8-K Arcutis Biotherapeutics, For: May 14May 14, 2024 4:07 PM Arcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 4:00 PM Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DMay 13, 2024 8:00 AM